 Home > Medical News > Medicines Company News > Zhifei Biorecombinant Group B meningococcal disease (Escherichia coli) received the clinical trial approval notice

Zhifei Biorecombinant Group B meningococcal disease (Escherichia coli) received the clinical trial approval notice

 Last Update: 2022-12-30
 Source: Internet
 Author: User

Tags

recycle number 5

flow rate meter

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Chongqing Zhifei Biological Products Co.
, Ltd.
(hereinafter referred to as the "Company") recently received a report from Beijing Zhifei Luzhu Biopharmaceutical Co.
, Ltd.
(hereinafter referred to as "Zhifei Luzhu"), a wholly-owned subsidiary, that the recombinant group B meningococcal disease (Escherichia coli) independently developed by Zhifei Luzhu has obtained the notice of approval for drug clinical trials by the National Medical Products Administration (notification number: 2022LP02028), agreeing that this product will carry out clinical trials in people aged 3 months to 50 years and 3 months to 5 years old, respectively
。 The company will carry out relevant clinical trial work
as soon as possible according to the requirements of the clinical trial approval notice.

Epidemic meningitis (flow brain) is acute purulent meningitis caused by Neisseria meningitidis, with the characteristics of acute onset, rapid progression, strong contagiousness, high case fatality rate, high disability rate, etc.
, the vast majority of flow brain is caused by group A, group B, group C, W135 group and group Y meningococci
.
Meningococci group B have become the main pathogen
causing meningococcal meningitis in major developed countries.

This recombinant group B meningococcal disease vaccine adopts recombinant technology to prevent meningococcal meningitis caused by meningococcus group B, and has a wide
range of market application prospects.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.